NexMed, Inc., an emerging drug developer, has received a Notice of Allowance from the US Patent and Trademark Office, for its US patent application entitled, "Prostaglandin Compositions and Methods of Treatment for Male Erectile Dysfunction." The 37 allowed claims extend to NexMed's proprietary topical treatment for erectile dysfunction - Alprox-TD, and specifically, to the product's enabling technology, formulation and method of treatment.

Richard J. Berman, CEO. of NexMed, commented, "This key patent when issued, will augment the nine issued US patents currently covering Alprox-TD, and provides NexMed with exclusivity to the year 2017. As important, receipt of this patent further strengthens NexMed's intellectual property portfolio, which currently includes over 200 US and international patents issued and/or pending."